Gut Microbiota and Metabolomic Profiles in Myasthenia Gravis Patients and Controls

29 myasthenia gravis patients and 10 healthy controls show distinct gut dysbiosis and metabolic disturbances. The dataset includes results from 16S rRNA sequencing and untargeted metabolomics, identifying 232 discriminative microbial taxa and 567 altered metabolites. Yunan Shan authored this research, which was last updated on April 23, 2026.

Use Cases

• Train a diagnostic classifier based on the 567 altered metabolites identified.
• Analyze correlations between microbial taxa like Faecalibacterium prausnitzii and clinical severity scores.
• Investigate metabolic pathway disruptions in cholinergic synapse or bile secretion pathways mentioned in the KEGG analysis.
• Explore the relationship between depleted short-chain fatty acids and disease state for potential therapeutic targets.

Strengths

• Integrated multi-omics data from 16S rRNA sequencing and UHPLC-Q-TOF MS metabolomics on the same cohort.
• Identified 232 discriminative microbial taxa and 567 significantly altered metabolites with statistical thresholds (VIP > 1.0, P < 0.05, FDR q < 0.05).
• Reported a Random Forest metabolite model with an AUC of 1.0 for distinguishing patient groups.
• Released under a permissive CC-BY-4.0 license for reuse.

Limitations

• The dataset is very small at 12.0 KB, suggesting it contains summary results rather than raw sequencing or spectral data.
• Row count and column-level documentation are unknown, limiting assessment of data structure and granularity.
• The sample size is limited to 39 total participants (29 patients, 10 controls), which may affect statistical power and generalizability.

Provenance

Source

Yunan Shan via figshare.

Collection Method

Fecal samples analyzed with 16S rRNA sequencing and untargeted metabolomics (UHPLC-Q-TOF MS).

Freshness

Last updated 2026-04-23 05:35:45.